ImmunoTargets and Therapy (Jul 2021)
Targeting CD22 for the Treatment of B-Cell Malignancies
Abstract
Nikesh N Shah,1 Lubomir Sokol2 1Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Lubomir SokolDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USAEmail [email protected]: Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.Keywords: CD22, epratuzumab, inotuzumab ozogamicin, bispecific antibody, chimeric antigen receptor, lymphoma, acute lymphoblastic leukemia
